Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Quorum sensing inhibitors for pulmonary delivery as a novel treatment against Pseudomonas aeruginosa

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Presentation
  • By: SOU, Tomás (Uppsala University, Pharmacy, Uppsala, Sweden)
  • Co-author(s): Tomás Sou: Department of Pharmacy, Uppsala University, Uppsala, Sweden
    Christel Bergström: Department of Pharmacy, Uppsala University, Uppsala, Sweden
    Miguel Cámara: School of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, United Kingdom
    Fadi Soukarieh: School of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, United Kingdom
    Michael Stocks: School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, United Kingdom
    Paul Williams: School of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, United Kingdom
    Irena Kukavica-Ibrulj: Institut de biologie intégrative et des systèmes, Université Laval, Québec, Canada
    Roger C. Levesque: Institut de biologie intégrative et des systèmes, Université Laval, Québec, Canada
  • Abstract:

    Backgrounds

    Pseudomonas aeruginosa exhibits a high rate of resistance to many of the current therapies available. A novel class of anti-virulence agents, quorum sensing inhibitors (QSI), designed to suppress biofilm formation in P. aeruginosa, and therefore sensitise the bacteria to other antibiotic treatments, is currently being developed.

    Aims

    To

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses